ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1617

Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022

Eric Roberts1, Jing Li1, Nick Bansback2, Chien-Wen Tseng3, Steve Shiboski1, Gabriela Schmajuk4 and Jinoos Yazdany1, 1University of California San Francisco, San Francisco, CA, 2University of British Columbia, Vancouver, BC, Canada, 3University of Hawai'i John A. Burns School of Medicine, Honolulu, HI, 4UCSF / SFVA, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: Biologicals, Health Services Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Health Services Research II

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: The first infliximab biosimilar (infliximab-dybb) entered the U.S. market in 2016, and two additional products have subsequently been introduced (infliximab-axxq (2017) and infliximab-abda (2020)). Biosimilars have significant potential to slow drug spending; however, uptake in the U.S. has lagged behind other countries. We compared rates of biosimilar uptake for Medicare, Medicaid, and private insurance after each infliximab biosimilar approval from 2016 to 2022.

Methods: Data from RISE, a national registry with electronic health records from one-third of U.S. rheumatology practices, was used. We examined all bio-originator or biosimilar infliximab administrations for users ≥ 18 years from the release of -dybb (biosimilar #1) in November 2016 through March 2022 regardless of diagnosis among participants with Medicare, Medicaid or private insurance. Dual Medicare-Medicaid patients were assigned to Medicaid. We modeled the log odds of receiving a biosimilar as a function of a three-way interaction between time (month), time-window (windows between biosimilar market introductions), and insurance (Medicare, Medicaid, Private) adjusting for age, sex, race or ethnicity, and socioeconomic status (as measured by Area Deprivation Index (ADI)). We used cluster robust standard errors to account for repeated measures on patients. We reported patient demographics, and adjusted predicted probabilities of receiving a biosimilar by insurance type over time.

Results: Among 33,751 distinct patients, there were 422,388 administrations of infliximab products in RISE between November 2016 and March 2022, 40,401 (9.6%) of which were for a biosimilar. Overall, 56.1% of patients were ≥65 years; 67.6% were women; 75.4% white; 55.1% had Medicare, 3.9% had Medicaid, and 41% had private insurance (Table 1). Figure 1 depicts the predicted probability of receiving biosimilar infliximab over time by time-window and insurance. After -dyyb (biosimilar #1) came out, uptake for all insurances remained low at less than 10%. With -axxq (biosimilar #2) release, Medicaid was the only insurance to show rapid increase in uptake reaching 19% over 3 years (4 times increase) versus 14% and 7% for Medicare and private insurance. However, after -adba (biosimilar #3) release, both Medicaid and private insurance uptake skyrocketed, reaching similar rates around 40%. Meanwhile, Medicare uptake continued to remain modest at 24%.

Conclusion: Adoption of biosimilar infliximab was quickest for Medicaid, with private insurance catching up after the release of a third biosimilar. Medicare uptake lagged significantly. To reduce drug spending, efforts are needed to understand poor Medicare uptake of biosimilars such as manufacturer rebates for biologics, and lack of financial incentives to switch to biosimilars.

Supporting image 1

Table 1. Demographic characteristics of infliximab bio-originator or biosimilar recipients in RISE registry between April 2016 and March 2022.

Supporting image 2

Figure 1. Predicted probability and 95% confidence interval of receiving biosimilar infliximab over time by insurance type


Disclosures: E. Roberts: None; J. Li: None; N. Bansback: None; C. Tseng: Hawaii Medical Services Association Endowed Chair, 5, www.enavvi.com, 1; S. Shiboski: None; G. Schmajuk: None; J. Yazdany: Astra Zeneca, 2, 5, Aurinia, 5, Gilead, 5, Pfizer, 2.

To cite this abstract in AMA style:

Roberts E, Li J, Bansback N, Tseng C, Shiboski S, Schmajuk G, Yazdany J. Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/comparing-uptake-of-biosimilar-infliximab-among-patients-with-medicare-medicaid-and-private-insurance-in-u-s-rheumatology-practices-2016-2022/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-uptake-of-biosimilar-infliximab-among-patients-with-medicare-medicaid-and-private-insurance-in-u-s-rheumatology-practices-2016-2022/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology